Subscribe
Blinatumomab for B-cell ALL Relapse, IVIG for MIS-C, Review of Irritable Bowel Syndrome, and more

JAMA Editor’s Summary

Blinatumomab for B-cell ALL Relapse, IVIG for MIS-C, Review of Irritable Bowel Syndrome, and more

Editor's Summary by Mary McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the
March 2, 2021
ADVERTISEMENT
Wise-Formerly Transferwise

Blinatumomab for B-cell ALL Relapse, IVIG for MIS-C, Review of Irritable Bowel Syndrome, and more

Editor’s Summary by Mary McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the March 2, 2021 issue

ADVERTISEMENT
WP Engine Wordpress Hosting

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Proudly supported by:

cover
Javier Lozano - Market-Creating Innovation for Diabetes Care an inspiring conversation with Javier Lozano, Founder and CEO of Clínicas del Azúcar, a growing chain of "one-stop shops" for diabetes care in Mexico.